Skip to NavigationSkip to content


FDA sets out guidelines on cannabis derived drugs

Photo by FDA

The FDA has released their guidelines on the rules companies should follow when developing cannabis derived drugs.

The guidelines cover both drugs and treatments that contain cannabis oil and other compounds found in the plant. These guidelines include references for calculating weight for oral dosages and what online resources to use for clinical trials.

UK Home office reclassifies Epidyolex as a Schedule 5 drug

Photo by Steve Cadman

The Home Office has announced that the drug Epidyolex (cannabidiol) has been reclassified as a Schedule 5 drug, a move from a Schedule 2 substance under the Misuse of Drugs Regulation 2001.

NHS to fast track cannabis-based treatment for epilepsy

The NHS has fast-tracked the drug Epidyolex, a cannabidiol (CBD), to be available for epilepsy treatment through the NHS in England, starting on 6 January 2020.

The drug had been recommend for use in treating two types of epilepsy, Lennox-Gastaut and Dravet syndromes, back in November.

Doctors will be able to prescribe the drug Epidyolex with clobazam for eligible children with this disease. Clinical trials have shown this treatment could reduce seizures of up to 40% in some children.

British Pharmacists call for regulation on non-medicinal CBD products

Pharmacists are calling for more checks on products containing Cannabis derivative cannabidiol (CBD) that are sold in shops across the country.

At the moment cannabidiol oil is classified as a food supplement, and it has been recently added to a range of products like chocolate, coffee, tea and makeup. It’s a brand-new type of food so there is a grace period where it is allowed to be sold in shops, but the Food Standards Agency (FSA) has now asked manufactures to give specific information about the product.

FDA issues warning to CBD company Curaleaf

The FDA has issued a warning to Massachusetts-based CBD company Curaleaf over the firm’s use of unsubstantiated claims about the health benefits of cannabidiol (CBD).

The US regulator on 23 July, sent a warning letter to Curaleaf over claims it made that CBD could be used to treat among other conditions, cancer, Alzheimer’s disease, opioid withdrawal, pain and pet anxiety.

The warning comes amid a crackdown on companies making dubious claims about the positive health effects of CBD.

Synthetic, non-intoxicating CBD analogue treats seizures in rats

A synthetic, non-intoxicating cannabidiol (CBD)-analogue is effective at treating seizures in rats, according to researchers at the University of California, Davis.

The molecule, 8,9-Dihydrocannabidiol (H2CBD) is a synthetic molecule which is structurally similar to the CBD. Mascal’s lab developed H2CBD from commercially available chemicals.

The UC Davis researchers tested H2CBD against CBD, in rats with induced seizures. Both drugs were found to be equally effective in treating seizures in rats.

GW Pharma's Epidiolex scores in rare childhood onset epilepsy Phase 3 trial

GW Pharma’s Epidiolex has shown positive Phase 3 trial results for the fifth time in a row, after meeting primary endpoints in a randomised, double blind, clinical study of patients with Tuberous Sclerosis Complex (TSC), a rare form of childhood onset epilepsy.

The CBD-based drug reduced seizures by 48.6% and 47.5% from baseline at doses of 25 and 50 mg/kg/day in patients with TSC, compared to a rate of 26.5% for placebo.

CBD could be used to deliver drugs into the brain, research shows

Cannabidiol (CBD), one of 113 cannabinoids in cannabis plants, could be used to deliver medicines into the brain, according to research published in the journal Molecular Pharmaceutics.

The non-psychoactive cannabinoid could act as a Trojan horse in helping drugs slip through the blood brain barrier (BBB) in the brains of mice, the research says.

The BBB consists of a layer of tightly linked cells that line capillaries in the brain thus preventing substances from entering or exiting the brain.

CBD dampens activity in brain regions associated with psychosis, study shows

Cannabidiol (CBD), one of the major constituents of cannabis, may be beneficial for patients with psychotic disorders due to its ability to modulate activity in brain regions associated with psychosis, a study published in the journal JAMA: Psychiatry has shown.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches